Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats

Experimental Biology and Medicine

Volumn 233, Issue 10, 2008, Pages 1301-1308

  Ancha, Hanumantha R ^a,b   Kurella, Ravi R ^a   McKimmey, Christine C ^a   Lightfoot, Stanley ^a   Harty, Richard F ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Affairs Medical Center   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Tocopherol; 5 ASA; Ascorbic acid; Colitis; Phenyl butylnitrone

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; MESALAZINE; MYELOPEROXIDASE; NITRONE DERIVATIVE; PHENYLBUTYLNITRONE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; AMINE OXIDE; ANTIOXIDANT; N TERT BUTYL ALPHA PHENYLNITRONE; PHENYL-N-TERT-BUTYLNITRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DESCENDING COLON; DRUG POTENTIATION; ENZYME ACTIVITY; MALE; MICROSCOPY; MONOTHERAPY; NONHUMAN; RAT; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; INTESTINE MUCOSA; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; COLITIS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; INTESTINAL MUCOSA; MALE; MESALAMINE; RATS; RATS, SPRAGUE-DAWLEY; TRINITROBENZENESULFONIC ACID; VITAMIN E;

EID: 54549098271     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0805-RM-140     Document Type: Article

References (34)

1. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52:2015-2021, 2007.
2. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Ailment Pharmacol Ther 16:1997-2015, 2002.
3. 2 through enhancement of NF-kB activity in lipopoly-saccharide-activated human primary monocytes. J Immunol 175:5423-5429, 2005.
4. Allen RG, Trezini M. Oxidative stress and gene regulation. Free Radical Biol Med 28:463-499, 2000.
5. Allen RG. Oxygen-reactive species and antioxidant responses during development: the metabolic paradox of cellular differentiation. Proc Soc Exp Biol Med 196:117-129, 1991.
6. McCubrey JA, Franklin RA. Reactive oxygen intermediates and signaling through kinase pathways. Antioxid Redox Signal 8:1745-1748, 2006.
7. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ulrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159:283-300, 2003.
8. Spitz DR, Azzam EI, Li JJ, Guis D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23:311-322, 2004.
9. Xavier RF, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434, 2007.
10. Nielsen OH, Munck LK. Drug insights: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4:160-170, 2007.
11. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Ostroff K. Mesalamine inhibits activation of transcription factor NF-kB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95:3452-3457, 2000.
12. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 95:3343-3345, 2000.
13. Keshavarzian A, Morgan G, Sedghi S. Role of reactive oxygen metabolites in experimental colitis. Gut 31:786-790, 1990.
14. Loguericio C, D'Argenio G, Delle Cave M. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis 35:635-641, 2003.
15. Rachmilewitz D, Karmeli F, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37:247-255, 1995.
16. Yoshida Y, Iwai A, Itoh K, et al. Role of inducible nitric oxide synthase in dextran sulfate sodium-induced colitis. Ailment Pharmaco Ther 14: 26-32, 2000.
17. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, Grisham MB, Ross CR, Granger DN. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 194:1207-1218, 2001.
18. Ardite E, Sans M, Panés J, Romero FJ, Pique JM, Fernandez-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. La Invest 80:735-744, 2000.
19. Naito Y, Takagi T, Ashikawa T, Handa O, Matsumoto N, Yagi N, Matsuyama K, Yoshida N, Yoshikawa T, Kotake Y. α Phenyl-N-tert- butylnitrone provides protection from dextran sulfate sodium-induced colitis in mice. Antioxidants Redox Signal 4:195-206, 2002.
20. Siddiqui A, Ancha HR, Tedesco D, Lightfoot S, Stewart CA, Harty RF. Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis. Dig Dis Sci 51:698-705, 2006.
21. 2 and NO/iNOS activities by the antioxidant N-acetylcysteine plus mesalamine promotes mucosal healing in a rodent model of colitis. Gastroenterology 132:A-568, 2007.
22. Schneider C. Chemistry and biology of vitamin E. Mol Nutr Food Res 49:7-30, 2005.
23. Traber MG, Atkinson J. Vitamin E antioxidant and nothing more. Free Radic Biol Med 43:4-15, 2007.
24. Kotake Y. Pharmacologic properties of phenyl N-tert-butylnitrone. Antioxid Redox Signal 1:481-499, 1999.
25. Isozaki Y, Yoshida N, Kuroda M, Takagi T, Handa O, Kokura S, Ichikawa H, Niato Y, Okanoue T, Yoshikawa T. Effect of a novel water-soluble vitamin E derivative as a cure for TNBS-induced colitis in rats. Int J Mol Med 17:497-502, 2006.
26. Tan PH, Sagoo P, Chan C, Yates JB, Campbell J, Beutelspacher SC, Foxwell BM, Lombardi G, George AJ. Inhibition of NF-kB and oxidative pathways in human dentritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 174:7633-7644, 2005.
27. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine. Cell Mol Life Sci 60:6-20, 2003.
28. Li Y, Schellhorn HE. New developments and novel therapeutic perspectives for vitamin C. J Nutr 137:2171-2184, 2007.
29. Linster CL, Van Schaftingen E. Vitamin C: biosynthesis, recycling and degradation in mammals. FEBS 294:1-22, 2006.
30. Halsted CH. Absorption of water-soluble vitamins. Curr Opin Gastro- enterol 19:113-117, 2003.
31. Maulen NP, Henriquez EA, Kempe S, Carcamo JG, Schmid-Kotsas A, Bachem M, Grünert A, Bustamonte ME, Nualart F, Vera JC. Up- regulation and polarized expression of the sodium-ascorbic acid transporter SVCT 1 in post-confluent differentiated Ca Co-2 cells. J Biol Chem 278:9035-9041, 2003.
32. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 69:1086-1107, 1999.
33. Kruidenier L, Kuiper I, Lamers CBHW, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 201: 28-36, 2003.
34. Buffinton GD, Doe WF. Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. Free Radic Res 22:131-143, 1995.